Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (745)	3/27/2008 4:58:03 PM
From: idos	Read Replies (1) \| Respond to of 804

You're right, Thalomid's exclusivity is not protected by COM patents (it has been in the public domain for a number of years) but rather by patents around the S.T.E.P.S. program governing its use, administration and post-market surveillance. Barr needs to design its own patient monitoring system that avoids the claims in the key '501 patent of T. The litigation is in its very early discovery phase and there is no trial date set. I think it will be a bit longer than next fall. Seems that their PDFs require Adobe 8.1.2.

To: tuck who wrote (745)	5/27/2010 3:21:44 PM
From: idos	Respond to of 804

Celgene says Barr withdrew generic Thalomid filing finance.yahoo.com On Thursday May 27, 2010, 8:10 am EDT SUMMIT, N.J. (AP) -- Celgene Corp. said Thursday that a competitor withdrew its application for a generic version of Celgene's cancer drug Thalomid. Celgene said Barr Laboratories withdrew the application, which had been filed in 2006 with the Food and Drug Administration. As a result, Celgene said it had dropped a 2007 patent infringement lawsuit against Barr. Celgene markets Thalomid, or thalidomide, as a treatment for multiple myeloma, which is a cancer that affects bone marrow. The company filed suit against Barr Pharmaceuticals in January 2007, saying Barr's proposed generic violated patents held by Celgene. Barr was acquired in late 2008 by Teva Pharmaceutical Industries Ltd., the world's largest maker of generic drugs.